Dynogen initiates phase 1b trial of DDP733 in gastroesophageal reflux disease (GERD)
Dynogen Pharmaceuticals, Inc. announced today that dosing has begun for a double-blinded, placebo controlled Phase 1b trial designed specifically to examine DDP733 on the functional changes associated with gastroesophageal reflux. In addition to examining safety, the trial will be powered to yield important efficacy data to support the use of DDP733 as a treatment for nocturnal gastroesophageal reflux (NGERD). Dynogen is developing DDP733 for NGERD as an adjunctive treatment with current GERD therapies. DDP733 is also being studied by Dynogen for irritable bowel syndrome with constipation (IBS-c) in a Phase 2 clinical study.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.